PICC-2: Toripalimab Plus Celecoxib Improves pCR in dMMR Locally Advanced Colorectal Cancer
9h agoen
From the article
Neoadjuvant immune checkpoint blockade has shown strong activity in mismatch repair-deficient or microsatellite instability-high locally advanced colorectal cancer. The PICC-2 trial evaluated whether adding the COX-2 inhibitor celecoxib to neoadjuvant […]
Continue reading on OncoDailyYou might also wanna read
NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer
clinicaltrials.gov·8d ago
Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation
clinicaltrials.gov·2d ago
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
clinicaltrials.gov·2d ago
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC
clinicaltrials.gov·19h ago
Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer
clinicaltrials.gov·19h ago
Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC
clinicaltrials.gov·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.